Business Context and Reporting Period
This Form 8-K is a current report filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on November 6, 2019. The registrant is incorporated in Nevada and trades on the Nasdaq Capital Market under the symbol EKSO. The report addresses Item 5.02 regarding compensatory arrangements for certain officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation grants and does not contain financial performance data.
Material Changes
On November 6, 2019, the Company's compensation committee approved equity awards under the Amended and Restated 2014 Stock Incentive Plan. Specific grants to Named Executive Officers (NEOs) include:
- Jack Peurach: 795,000 shares underlying options.
- Jack Glenn: 240,000 shares underlying options.
These options vest in 48 equal monthly installments commencing on December 6, 2019.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operations, or specific risk factors. It notes that full compensation details for the fiscal year ended December 31, 2019, will be reported in the upcoming Form 10-K or proxy statement.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2014 Stock Incentive Plan to assess dilution impact.
- Confirm the exercise price of the options granted to Jack Peurach and Jack Glenn.
- Review the upcoming Form 10-K for the full Summary Compensation Table for the fiscal year ending December 31, 2019.
- Check the vesting schedule compliance for the 48-month installment plan starting December 6, 2019.